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Abstract
Background: In conjunction with the spread of HIV infection, tuberculosis (TB) remains a major cause of illness and
death worldwide. The Ethiopian national report reveals that extra pulmonary tuberculosis is on the rise and that
case detection rate is exceeding that of smear positive or negative cases in many parts of the country. Different
studies indicated that host and/or pathogen related factors are associated with the rise of extra pulmonary cases.
However, the reason for this is not clearly known in our setting.
Methods: Specimens were taken from clinically suspected extra pulmonary patients and confirmed by cytology,
histopathology and culture. Deletion typing and Spoligotyping was utilized to identify the strains. The isolates were
then assigned to lineage using conformal Bayesian network (rules model) algorithm and dendrograms were drawn
using UPGMA methods. In addition, drug sensitivity test was done using the indirect proportion and 24 well plate
methods.
Results: Out of the 200 clinically suspected extra pulmonary tuberculosis patients, 106 (53 %) were between 15 and
35 years of age and 167 (83.5 %) were new while 33 (16.5 %) were retreatment cases. The culture yield was 29.5 %
(59). Of these only one was M. bovis and 58 were M. tuberculosis strains with 31 different spoligotype patterns
grouped into seven clusters. The largest cluster (ST53) comprised 12 (20.3 %) isolates. There was higher clustering of
CAS isolates in TBLN than in any other form of extra pulmonary tuberculosis cases. Resistance to rifampicin was
higher (22 %) than that for INH, STM and EMB (8.1 %, 5 % and 3 % respectively). Out of the 37 isolates tested for
resistance, only 2 isolates were resistant for both STM and INH and no MDR strain was found.
Conclusions: There is an ongoing active recent transmission among extra pulmonary tuberculosis in the study
areas as shown by the presence of clusters. Although no MDR case was observed, there is a risk of emergence of
MDR as noted from the high proportion of resistance to rifampicin. Detailed study at population level is
recommended to monitor its trend.
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Background
In conjunction to HIV, tuberculosis remains a major glo-
bal health problem. It causes ill-health among millions
of people each year and ranks as the second leading
cause of death from an infectious disease worldwide,
after the human immunodeficiency virus (HIV). Accord-
ing to the latest estimates, globally 8.6 million people de-
velop TB and 1.3 million died from the disease in 2012.
The South-East Asia and Western Pacific Regions col-
lectively accounted for 58 % of the world’s TB cases in
2012 and the African region had approximately one
quarter of the world’s cases [1].
In Ethiopia, the number of caseloads reported in all
forms of TB in 2012 was 143 503 which makes it one of
the largest reported cases in the world [1]. There are 22
high burden countries (HBCs), which accounts 81 % of
the estimated number of new TB cases (all forms) aris-
ing worldwide each year. Of these Ethiopia ranks in the
7th position after India, China, Indonesia, Pakistan and
South Africa. According to WHO (2013) estimate; the
prevalence, incidence and mortality in all forms of TB
were 224, 247 and 18 per 100,000 respectively [1] Based
on the national surveillance data in the year 2010/11 a
total of 159,017 TB cases were notified and the propor-
tion of new smear-positive, smear negative and Extra
Pulmonary Tuberculosis (EPTB) among all new cases is
32.7 %, 34.8 %, and 32.5 % respectively.
With the advent of HIV/AIDS the incident rate of
EPTB is also on the rise and becomes worldwide prob-
lem [2–5]. The disease is highly pronounced in countries
where HIV infection and incident TB rate is higher. Ac-
cordingly, EPTB accounts for 15 to 20 % of all forms in
people who do not have HIV but 53 to 62 % in HIV co-
infected individuals [6,7]. The case notification of extra
pulmonary tuberculosis is in Ethiopia is also higher and al-
most equal to that of smear positive and negative pulmon-
ary tuberculosis cases with a percentage of 33 each [8].
The development of DNA finger printing (genotyping)
of Mycobacterium tuberculosis isolates has provides a
better insight in understanding of the transmission of tu-
berculosis [9]. Genotyping outcome of the isolates to-
gether with epidemiological data assists researchers to
identify recent transmission and trace outbreaks. The
techniques can be utilized as a tool for epidemiological
studies to determine the overall diversity of Mycobacter-
ium tuberculosis strain that can help to address important
epidemiological questions such as the origin of an infec-
tion in patient’s household or community, and the spread.
It also assists in an early detection of organisms with ac-
quired drug resistance [9, 10]. Although a number of mo-
lecular techniques are available, spoligotyping is selected
for a number of reasons. It is relatively simple, rapid and
good for strains with low copy numbers of IS6110. More-
over it helps to identify and type strains simultaneous [11].
It has been indicated that strain variation associated
with clinical manifestation of tuberculosis [12, 13] and
explained that some strain possess superior ability than
others and becomes highly virulent to causes extra thor-
acic tuberculosis and disseminated out of the lung [12,
14–16]. Moreover, recent studies reported the variation
in the genetic diversity of tuberculosis causing pulmon-
ary and extra pulmonary tuberculosis in different cities
of Ethiopia [17–22]. However, data on extra pulmonary
tuberculosis in Addis Ababa was not reported. There-
fore, in this study we tried to evaluate the genetic
diversity, clinical manifestation and drug sensitivity of
mycobacterial isolates causing extra pulmonary tubercu-
losis is Addis Ababa city.
Materials and methods
Study population
A total of 200 clinical suspects of extra pulmonary TB
patients that are referred and/or admitted in four refer-
ral hospitals found in Addis Ababa, Ethiopia (Black lion,
St. Peter, St. Paul, and ALERT hospitals) from April
2012 to July 2013 and gave their written consent were
considered. Using Pre structured questionnaires demo-
graphic, epidemiological and clinical data were collected.
Patients were informed about the objectives and benefits
of the study and who written consents were considered
for the study. Children under 18 years of age were re-
quired to have guardian’s or parent’s informed consent
and children between 12–18 years were requested for
assent. The ethical approval was obtained both from the
national and AHRI/ALERT Ethics Review committee.
Specimen collection and processing
Specimens from extra pulmonary sites were collected by
experienced health professionals (Medical doctors, Health
Officers, Nurses) following standard procedure. Various
fluids such as pleural, peritoneal and synovial fluids will be
collected in sterile containers with anticoagulant. Tissue
specimens were collected without fixatives. Where uro-
genital tuberculosis is suspected, three consecutive early
morning urine samples without preservatives were taken.
All clinical specimens were immediately transported to
AHRI laboratory in an icebox.
Specimens from non-sterile sites were decontami-
nated by N-acetyl-L-Cycteine sodium hydroxide tech-
niques and the sterile ones such as cerebrospinal,
pleural, ascetic and Synovial fluids, were directly centri-
fuged at 3000 rpm for 15 min without decontamination
[23]. The specimens was then be examined for AFB
and inoculated on to Lowenstein Jensen medium (LJ
medium) and then incubated at 37 °C, 7%CO2 for 6–8
weeks in slanted position as described on modified
petroff ’s method [24].
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Drug susceptibility test
The culture positive isolates were tested for drug sensi-
tivity against first and second line anti-tubercular drugs
following 24-well plate methods as described [25].
Stock solution for the first line drugs: INH, RIF, ETH
and STR, (Sigma, St. Louis, USA) were prepared at
1 mg/ml concentration using distilled water for all but
DMSO for rifampicine. It was then filter sterilized
through 0.2 μm size filter and stored at -20Co until used.
Nineteen gram of 7H10 Middle brook agars was dis-
solved (Becton Dickinson and Company) in 900 ml of
distilled water at 50–60 °C temperature and 5 ml gly-
cerol (BDH Laboratory Supplies, England) was added
and autoclaved at 120 °C for 15 min. one hundred milli-
liter (10 %) Oleic acid-dextrose-catalase (OADC, Becton
Dickinson and Company) was mixed after cooling it to
50 to 60 °C.
Working drug concentrations of the drugs including
the critical concentration (Table 1) were mixed with
sterile 7H10 media and dispensed in 3 ml. volume in 24
well plates. Two wells with drug free media were used as
negative controls.
Drug sensitivity test was done based on modified
proportion method in 24-well DST plate [25]. Deter-
mination of the susceptibility of isolates to anti‐myco-
bacterial drugs was done by standard indirect drug
susceptibility test. All the isolates were tested for
INH, RIF, EMB, STR, PAS, KAM and OFL resistance
following the standard protocol [25].
A loop from culture was suspended in (ependorff ) dis-
tilled water and two concentrations: McFarland turbidity
1 and 1:100 dilution of it were prepared. Ten μl from
McFarland turbidity 1 suspension was inoculated to 22
wells with drug incorporated media and two drug free
control media were inoculated with the two dilutions:
McFarland turbidity 1 and 1:100 dilution. The plates
were then incubated at 5 % CO2 concentration and
35oC temperature for 3–4 weeks and checked for
growth at week intervals. Growth at concentrations ≥
critical was considered as resistant.
HIV testing
Screening for HIV was done for only patients with un-
known HIV status according to the Ethiopian National
Guide lines. If the patient is found be positive, he/she was
referred to the appropriate heath facilities rendering HIV
care and follow up according to national guide lines [26].
Species and strain identification
Species identification was done by using molecular
methods. Molecular identification of the isolates was
done based on the absence or presence of mycobacter-
ium tuberculosis complex chromosomal region of differ-
ence (RD) deletion loci. The genome of the isolates was
analyzed by multiple PCR assay for absence or presence
of RD by using RD9 as previously described a [27].
Spoligotyping was employed for strain identification
using commercially available kits using a commercially
available kit (Isogen Bioscience BV, Maarssen, the
Netherlands). The spacer sequences are interspersed be-
tween repetitive sequences and are variably present or
absent in a given MTBC isolate. Examination of 43 of
these unique spacer sequences results in a strain-specific
fingerprint. The method is based on CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats) region
also called (direst repeat) DR region of Mycobacterium
tuberculosis using the primers DRa (5’GGTTTTGG
GTTTGAACGAC3’) and DRb (5’CCGAGAGGGGACG
GAAAC3’) [28]. This direct region was amplified by
using the DRa and DRb primers. The amplified DNA
was hybridized to inter DR spacer oligonucleotides
which are covalently bound to the membrane. Subse-
quently the amplified DNA was then hybridized to a set
of 43 oligonucleotide probes by reverse blotting. The
membrane then incubated with streptavidin peroxidase
conjugate. Finally enhanced chemo luminescence detec-
tion system (Amersham, Little Chalfont, United Kingdom)
was used and absence or presence of spacers was detected
by visualizing the black spots developed on the membrane
film.
Database comparison
The spoligotyping patterns obtained were entered to the
international spoligotyping database, SpolDB4.0 (http://
www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/) and
assign in to the existing SIT (Spoligotype International
Type) number. The spoligotypes not earlier described
(orphans), not found in SpolDB4 data base, were also
assigned to families and sub lineage using SPOTCLUST
ID web based algorithm model SpolDB3 tanking the
highest probability percentage (99 %) (http://tbinsight.cs.
rpi.edu/run_spotclust.html).
Phylo-genetic lineages of Mycobacterium tuberculosis
complex were done using lineages: four http://tbinsight.
cs.rpi.edu/run_tb_lineage.html insight/tblineage.html web.
Finally relationships among strains were also analyzed
by drawing dendrgram using Unweighted Pair Group
Method with Arithmetic mean (UPGMA) (http://genomes.
urv.cat/UPGMA/).
Table 1 Test concentrations of Anti-Tb drugs
Drug types Test concentrations Solvents
INH 0.064 0.125 0.2 1.0 dH2O
RIF 0.25 1.0 DMSO
EMB 1.0 2.0 5.0 8.0 dH2O
STM 2.0 dH2O
The red ones indicated critical concentrations
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Result
Demographic characteristics
Out of the 200 EPTB suspects who came to the four re-
ferral hospitals from different parts of the country within
the study period, 94 (47 %) were males and 106 (53 %)
were females. Their age ranged from 1 to 79 years with
mean age of 25.91 (±15.67) years. However, the majority
of them, 106 (53 %), were between 15 and 35 years.
Most, 167 (83.5 %), were new and 33 (16.5 %) retreat-
ment groups. Among the study participants, 55.1 % were
married, 28.1 % single, 7.5 % divorced and 32 % under-
age (Table 1).
Clinical presentation of patients
Based on the clinical presentation, 91.5 % of the enrolled
patients fall into three major disease categories: 116
(58 %) tuberculous lymphadenitis or lymph node tuber-
culosis (TBLN), 53 (26.5 %) disseminated tuberculosis
(DTB), 14 (7 %) pleural tuberculosis (PLTB) and the rest
9.5 % were mixes of scrotal, skin, peritoneal, leg, breast
and peritoneal TB (Fig 1). Of the total sample popula-
tion, 62 (31 %) were HIV positive, 123 (61.5 %) negative
and 15 (7.5 %) of an unknown status. The 62 HIV posi-
tive patients were also categorized as TBLN [29], DTB
[25], and, PLTB [3], and axial, bone and peritoneal TB (1
each) (Fig. 1). The highest HIV positive prevalence was
in the age group 25–35 and among married subjects. In
addition, of the total seventy five (37.5 %) were alcohol
consumers and 15 (7.5 %) diabetic patients (Table 2).
The data also showed that from those confirmed by
culture as EPTB cases, 36.7 % were HIV co-infected
(Fig. 2).
HIV and EPTB
Considering samples resulting culture positive as con-
firmed extra-pulmonary TB, we tried to assess it’s the re-
lationship with HIV. As a result, the chi square test
result shows that there is a significant relationship be-
tween HIV and extra-pulmonary tuberculosis with a p
value =0.037 and χ2 = 6.620 (Table 3).
Strain analysis
Spoligotyping of isolates from EPTB cases showed that
the 59 isolates display 31 different patterns. Of these 35
(59.3 %) strains could be grouped into 7 different clus-
ters (Table 4). The largest cluster (ST53) comprised 12
(20.3 %) isolates, followed by ST149 (10.1 %) and ST25
(8.47 %) with 6 and 5 isolates, respectively. ST910 and
ST21 comprised of 3 (5.8 %) isolates for each. The rest
were unique (non-clustered) spoligotype patterns in 24
(40.7 %) of the isolates.
All the 59 EPTB isolates (both the new and isolates
found in the data base) were assigned in to families and
sub lineage using SpolDB4 for the known and SpotClust
ID for the new isolates. Hence, the result showed that
the T1 lineage is the dominant followed by CAS, T3 and
Harlem with a percentage of 40.7, 16.2, 13.6 and 10.2 re-
spectively (Fig. 3).
In addition, the isolates were also classified into
lineage and the result revealed that 69.5 % of the isolates
were Euro American lineage followed by East African
Indian (CAS) and Indo-Oceanic with 20.3 % and 5.1 %
respectively. The rest 5.1 % comprised of Beijing, East
Asian and Mycobacterium bovis each having one isolate
(Fig. 4).
Fig. 1 Pie chart of EPTB suspected cases
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Dendrogram built from 59M. tuberculosis and one M.
bovis Samples based on spoligotyping results using Un-
weighted Pair Group Method with Arithmetic mean
(UPGMA). Cophenetic correlation coefficient of the
dendrogram is 0.827.
The genetic distance was built using the unweighted
pair group method with arithmetic mean (UPGMA) al-
gorithm [30] and it showed that the strains clustered in
to families: T1, T3, H and CAS. The distance of the
measurement is 1 (Fig. 5).
Relationship between infection sites and isolates family
Since samples were taken from different infection
sites, we analysed to see whether there is an associ-
ation between the sites and the family of the isolates
or not. Accordingly, the chi square test showed that
Table 2 Demographic characteristics of EPTB patients
Variables HIV result P Χ2 % of HIV
+ ves+Ve -Ve unknown
Age category <5 3 17 1 4.84
5-15 5 22 1 8.06
15-25 8 38 6 12.90
25-35 25 25 4 0.001 30.31 40.32
35-45 14 12 1 22.58
>45 7 8 3 11.29
Sex Male 29 57 6 46.77
Female 33 66 9 0.88 0.238 53.22
Married 34 43 6 54.83
Marital Status Unmarried 13 31 6 20.97
Divorced/Widow/er 6 3 1 0.004 18.91 9.68
Under age 9 46 2 14.52
Alcohol consumption Yes 31 40 4 50
No 31 83 11 0.045 6.186 50
Case type New 40 112 15 64.52
Retreatment 21 11 0 0 33.87
Diabetes Mellitus Yes 5 8 2 8.07
No 57 115 13 91.94
Positive
Fig. 2 culture result Vs HIV positivity
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there is no relationship between infection site and
family/strain types (P = 0.889). However, the CAS
strain is found mostly in lymphadenitis: 9 from cer-
vical and 1 axillary (Fig. 6).
Drug sensitivity
Anti-Mycobacterial Drug sensitivity test for both first
and second line drugs: INH, RIF, EMB and STM, re-
vealed that the proportion of resistance to rifampicin
was higher (22 %) and that of INH, STM and EMB were
8.1 %, 5 % and 3 % respectively. Out of the 37 isolates
Table 3 Association between HIV and EPTB
Value χ2 Asymp. Sig.(2-sided)
Pearson Chi-Square 6.620 .037
Linear-by-Linear Association .001 .979
N of Valid Cases 200
















1 111111111113771 1 East Asian (Beijing) Beijing/W lineage Beijing family 1 1.69
2 111111117761771 4 East-Asian LAM3 1 1.69
3 700000007177771 910 Indo-Oceanic U Family 36 3 5.08
4 777000377760771 149 Euro-American T3 6 10.1
5 777777777760771 53 Euro-American T1 12 20.3
6 777777777720771 50 Euro-American H3 1 1.69
7 777777777760751 612 Euro-American T1 1 1.69
8 777775777760731 584 Euro-American T1 1 1.69
9 777737777760771 37 Euro-American T1 4 6.77
10 577777607760771 866 Euro-American LAM9 1 1.69
11 777777777420771 777 Euro-American H3 1 1.69
12 777777754020771 883 Euro-American H1 1 1.69
13 777777774020771 47 Euro-American H1 1 1.69
14 777737770000000 56 Euro-American U Family34/ EAI1/ 0.99 1 1.69
15 703777740003171 25 East-African Indian (CAS) CAS 5 8.47
16 703377400001771 21 East-African Indian (CAS) CAS 3 5.08
17 777777377760771 40 Euro-American T4 1 1.69
18 777737777420771 35 Euro-American H4 1 1.69
19 603777740003771 952 East-African Indian (CAS) CAS 1 1.69
20 577777002060771 788 Euro-American T1 1 1.69
21 007777707760771 1889 Euro-American U LAM9 0.688 1 1.69
22 776737777760771 New Euro-American T1 0.99 2 3.39
23 777317347760671 New Euro-American T1 0.99 1 1.69
24 777777747420771 New Euro-American H3 0.77 1 1.69
25 377000377760771 New Euro-American T3 0.99 1 1.69
26 777737747760760 New Euro-American T1 0.99 1 1.69
27 703777600003171 New East-African Indian (CAS) CAS 0.99 1 1.69
28 703701740003171 New East-African Indian (CAS) EAI4 0.933 1 1.69
29 006737777760771 New Euro-American T1 0.99 1 1.69
30 511000377760771 New Euro-American T3 0.99 1 1.69
31 602343761000200 New M. bovis 1 1.69
59 100 %
CAS (Central Asian Strain), EAI (East African Indian), H (Haralem), LAM (Latin American), T (ill defined)
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tested for resistance, only 2 isolates were resistant for
both STM and INH and no MDR was found (Table 5).
Discussion
Before the beginning of the HIV epidemic, ∼85 % of re-
ported tuberculosis cases were limited to the lungs [31].
Latter, this proportional distribution was considerably
different among persons with HIV infection and then
EPTB came out of the shadow and becoming a growing
problem [29]. At present, Extra-pulmonary tuberculosis
is on the increase globally including Ethiopia [32, 33].
The global increase is believed to be increased by HIV
related immune incompetence. In addition to this global
picture, the national report also shows that it covers al-
most one third of the total TB case reports [33].
In agreement to these observations, our result showed
that among the total suspected cases, 62 (31 %) were
HIV positive. We have also found that 21 (35 %) were
HIV positive from culture confirmed EPTB cases. How-
ever, this figure is higher and accounts for 53 to 62 % in
HIV co-infected individuals whereas only 15 to 20 % of
all forms of TB in HIV negative patients [34, 35]. Differ-
ent studies indicated that EPTB increased significantly
with the pandemic of HIV and the co-infection rate is
higher in developing countries where the prevalence is
higher. It has been well established that EPTB is higher
among HIV positives. Earlier reports of Abate et al.
(2003) from Tikur Anbessa hospital in Addis Ababa
showed that the proportion of newly diagnosed EPTB
patients among HIV patients was more than those of
smear positive and smear negative pulmonary TB [36]
and other studies also showed that HIV is associated
with Extra pulmonary tuberculosis [37, 38]. HIV, poor
living condition and inadequate health care contribute
Fig. 4 Percentage distribution of Major lineages
Fig. 3 Percentage of Family types of EPTB isolates
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to the high level of TB in developing countries (Fanning
1999; Sharma and Mohan, 2004).
The higher proportions of HIV within the age range
25–35 and the higher frequency of HIV and EPTB in fe-
male patients was also higher than in males. As sug-
gested in other studies, this might be due to differential
exposure of women to infectious TB patients, and med-
ical care compared with men [6, 39].
EPTB has different manifestations based on the organ
affected and the distribution varies in different studies.
Mohammed et al., (2003) reported that lymph node tu-
berculosis constituted 40 % of all TB cases and 72.8 % of
the clinical suspects in Southern Ethiopia [40]. In agree-
ment to the above observations, in our study lymph-
adenitis, disseminated TB and Pleural TB were the three
major types. As shown in Fig. 1, 65 % of the confirmed
cases were lymph node tuberculosis including axillary,
inguinal and cervical. This is also similar to the study re-
ported from Germany [5]. In contrary, the most com-
mon sites involved were the bone/joints and lymph
nodes in the United States [4], while the genitourinary
system and skin were the common sites in a report from
Hong Kong [41]. These differences may be attributable
to either host or pathogen related factors as well as ac-
cess to patient sampling in the clinical settings. Though,
strong statistical association is not established, our study
showed that there is dominance of certain strains (Fig. 5)
and clusters of CAS found only lymphadenitis (Fig. 6).
Analysis of the diversity of Mycobacterial isolates and
data base comparison is essential in determining the dis-
tribution of M. tuberculosis complex in different geo-







Fig. 5 Dendrogram of extrapulmonary tuberculosis isolates based on genetic similarity of DR regions. CAS= Central Asian strain, T= ill-defined
lineage, H= Haarlem lineage
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insight to understand the dynamics of current transmis-
sion and dominant strains associated with the disease
pattern. In line with this, we described the strain diver-
sity of 59M. tuberculosis isolates from extra pulmonary
tuberculosis patients in Addis Ababa.
There is geographical sub structuring within the Euro-
American lineage and most other areas were also associ-
ated with only one or two lineages. However, all six main
lineages were represented in Africa [42]. In addition,
there is an observation of Indo-Oceanic lineage, the
most ancestral of the six lineages, which was associated
with East Africa. In agreement to this justification, our
isolates from EPTB cases were categorized in to five lin-
eages with the absence of Mycobacterium africanum and
M. caprae. Accordingly Euro American lineage (71.1 %),
Indo Oceanic (5.1 %), East Asian (3.4 %) East Africa In-
dian (18.6 %) and M. bovis (1.6 %) (Fig. 4).
In this study, the distribution of strains showed that
the T1 family is the dominant followed by CAS, T3 and
Harlem with a percentage of 40.7, 16.2, 13.6 and 10.2 re-
spectively. In line with this finding it was reported that
the T family and other which were categorized under
Euro-American and Indo-Oceanic were predominantly
found in extra pulmonary cases [43] and also 42 % of
isolates from tuberculous lymphadenitis were belonging
to the Harlem genotype [44].
The data base comparison using SpolDB4 to assign
into Shared International Number, spoligotyping pattern
showed that the largest cluster, ST53 comprised 12
(20.3 %) isolates, followed by ST149 (10.1 %) and ST25
(8.47 %) with 6 and 5 isolates, respectively. ST910 and
ST21 comprised of 3 (5.8 %) of isolates for each. The rest
were unique (non-clustered) spoligotype patterns in 24
(40.7 %) of the isolates. In addition, all the spoligotypes
not found in SpolDB4 data base (orphans), were also
assigned to families and sub lineage using SPOTCLUST
ID web based algorithm model SpolDB3 (http://tbinsight.
cs.rpi.edu/run_spotclust.html). Accordingly most of the
new strains obtained from extra-pulmonary cases were
assigned to T1 family with a probability of 0.99. Based on
these assignments, the T1 lineage was dominant and
accounted for 21 (35 %). This might be due to clonal asso-
ciation and an active transmission of this family with in
the society as it has been indicated on a number of re-
search it is an indication of active transmission in the
community [45–49].
Evidence suggests that there is strain-specific differ-
ence in virulence and immunogenicity. Moreover, strain
variation might be attributed to the variation in clinical
appearances and some strains are more virulent and
possess greater ability to disseminate than others [50]. In
this study, the isolates were categorized into different
Table 5 Drug sensitivity of EPTB isolates in percent
INH RIF EMB STM INH &STM INH, EMB & STM
Resistant 3 (8 %) 8 (21.6 %) 1 (2.7 %) 2 (5.4 %) 1 (2.7) 1 (2.7 %)
Susceptible 34 (92 %) 29 (78.4 %) 36 (97.3 %) 35 (94.6 %) 36 (97.3 %) 36 (97.3 %)
CAS dominant on 
Cervical LN
Lineages 
Fig. 6 Distribution of the different families at the collection sites, p= 0.889
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sub lineages. Accordingly, the T1, H, CAS, ETH2/U and
T3 cover more than 60 % of the EPTB isolates; the T1 is
the dominant, widely distributed and isolated from dif-
ferent parts of the body whereas CAS strains are clus-
tered with close similarity and isolated from cervical and
axillary samples only. Out of the total 59 isolates 10
were categorized under CAS1 family, of these 9 were
found in lymph node tuberculosis. Showing there is
dominance of CAS1 high in TBLN. In line with this,
studies from Pakistan showed that these strains were
also prevalent and accounted for 39 % of isolates form
both pulmonary and extra pulmonary cases [51]. Simi-
larly, Lari et al. (2009) reported that there is association
between the CAS strains and extra-pulmonary TB [52]
which might in part explained by the long established
link of extra-pulmonary tuberculosis TB with South
Asian of African origin patients that has been also re-
ported earlier. On the other hand, two strain families,
LAM3/F11 and W-Beijing, predominated in the South
African study [53]. However, in our study we found only
a single isolate of Beijing strains which is similar to stud-
ies conducted on the same area [54].
Earlier study conducted by Abate etal, (1998) on
retreatment cases in Addis Ababa showed that drug re-
sistance of pulmonary tuberculosis to one or more drugs
was 50 % and that of MDR TB was 12 % for that period
[36] Nevertheless, the overall primary drug resistance to
pulmonary tuberculosis was 15.6 % [55] and 21 % [56] in
studies conducted in Addis Ababa. According to the na-
tional survey (2003–2006), the percentage of MDR TB
in Ethiopia is 1.6 and 11.8 of new and retreatment cases
respectively. Similarly WHO reported that the % of new
and retreatment cases with MDR-TB were 1.6 and 12 re-
spectively [57].
Moreover studies revealed that the frequency of single
drug resistance in Extra pulmonary tuberculosis was
higher (13.3 %) and that of multiple drug resistance was
15.9 % [58] which is much higher than that reported by
the World Health Organization (3.6 %) [59]. Our study
showed that the proportion of resistance to rifampicin
(21.6 %) was higher and single drug resistance was lower
than the above study. However, another study conducted
in the eastern part of Ethiopia reported that 9.5 % resist-
ance against isoniazid and the rate of MDRTB was 1.1 %
[60]. An additional study also reported that the propor-
tion of resistance to Rifampicin (RMP) and isoniazid
were 17 (2.8 %) and 15 (2.5 %) respectively [61]. How-
ever, the resistance in our study to other first line drugs
were comparatively similar to these studies.
Conclusion
The study showed that the disseminated and lymphoid
tuberculosis is the most frequent forms of extra pulmon-
ary tuberculosis in Addis Ababa. Development of drug
resistance in the study isolates was low except for rifam-
picin and multi drug resistance was not found in the
study strain.
The Euro American and East African Indian Lineages
are the dominant lineage and SIT 53 strains were also. It
has also indicated that CAS appeared to be highly clus-
tered in TBLN than in other forms. A moderate level of
cluster formation suggested the presence of recent trans-
mission of TB in the area. The dominance and distribu-
tion of the T lineage might be delay in diagnoses of
EPTB cases, which will create a condition for dissemin-
ation or might suggest higher virulence of these strains
as compared to others. Whereas, the localization of CAS
strain within cervical areas needs further investigation.
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